Showing 1101-1110 of 1697 results for "".
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/pn1107dementia-pdf/31099/Effective teamwork and communication are crucial in managing dementia care, as highlighted by Dr. David S. Geldmacher in Practical Neurology. Drawing parallels from a volleyball game, Dr. Geldmacher emphasizes that successful dementia management mirrors the collaborative efforts seen in team sports.
- Disease-Modifying Therapies for Alzheimer's: New Drugs on the Horizonhttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/pn0508-ad-fea-pdf/31021/Advancements in Disease-Modifying Therapies for Alzheimer’s DiseaseAlzheimer’s disease (AD) currently impacts approximately 26.6 million individuals globally, with nearly five million cases in the United States. Projections indicate a potential 400% rise by mid-century, underscoring the urgent need
- Business Advisorhttps://practicalneurology.com/columns/practice-management/business-advisor/31437/Navigating Prescription Costs and Generic Substitutions in Epilepsy ManagementThe escalating costs of prescription medications present significant challenges for epilepsy patients, exacerbated by rising insurance premiums, increased co-pays, and higher deductibles. These financial strains often forc
- Expert Opinionhttps://practicalneurology.com/columns/practice-management/expert-opinion/31428/Understanding Eyelid Myokymia: A Benign Neurological PhenomenonEyelid myokymia, characterized by intermittent, fine, involuntary contractions of the eyelid muscles, is a condition frequently encountered in clinical neurology. Typically unilateral and localized to the lower eyelid, it presents as twi
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31243/Therapeutic Hypothermia: A Promising Neuroprotective Strategy for Cerebral IschemiaDespite the vast number of stroke research publications monthly, acute stroke treatment remains limited, with tissue plasminogen activator (tPA) being the sole approved therapy within a restrictive three-hour window.
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31285/Recent Advances and Insights in Neurology: August 2006Neurology continues to evolve with significant breakthroughs and research findings presented in recent studies and conferences. A notable development from the Aging Research Center at Karolinska Institutet introduces a predictive model for dement
- Bracing for the Medicare Shockwavehttps://practicalneurology.com/columns/practice-management/bracing-for-the-medicare-shockwave/31365/Impact of 2006 Medicare Reforms on Neurological Practice and Patient CareThe evolving landscape of Medicare in 2006 presents significant challenges and opportunities for neurologists and healthcare professionals. Recent adjustments in Medicare reimbursement rates have introduced uncertainty followin
- Are We Missing the Connection Between Headache and Fibromyalgia?https://practicalneurology.com/diseases-diagnoses/headache-pain/PN0805CvrFeature-pdf/31413/Dr. Robert L. Knobler’s August 2005 article in *Practical Neurology* critically examines the diagnosis of fibromyalgia syndrome (FMS) and its broader implications for understanding migraines and chronic pain in clinical practice. Knobler highlights the pervasive disregard and overdiagnosis of FMS, o
- 10 Tips for Managing Adolescent Epilepsyhttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pn0308-epilepsy-fea-pdf/31041/Managing Epilepsy in Adolescents: Addressing Unique Challenges for Optimal OutcomesEpilepsy management in adolescents presents distinct challenges that transcend typical age-related barriers, necessitating tailored approaches for effective treatment. As highlighted in the March 2008 issue of *Practi
- Will Generics Gobble Up The Neurology Market?https://practicalneurology.com/columns/practice-management/will-generics-gobble-up-the-neurology-market/31082/Generics Gain Ground in Neurology: Implications for Clinical PracticeThe landscape of neurology pharmacotherapy is shifting as generic medications increasingly replace brand-name drugs, promising substantial cost savings without compromising efficacy. As highlighted in the December 2007 issue of *Pr